The Body Covers: The 35th Annual Meeting of the Infectious Diseases Society of America
Impact of DMP-266, A New, Unapproved NNRTI, with Indinavir, and D4T
Dr. S. Riddler of the University of Pittsburgh reported for the DMP-266 clinical development team on the 48 week data for a cohort of asymptomatic patients treated with DMP-266 (200 mg/d), a nonnucleoside reverse transcriptase inhibitor, with Indinavir (800 or 1000mg/tid). The patients had a mean baseline plasma HIV RNA of 5.06 log10 copies of HIV RNA/ml and mean CD4 count of 283 cells/mm3. 71% had prior nucleoside therapy. In the course of the study, 42 of the 59 patients who initially enrolled added D4T to their regimen at 12 weeks, and all points had their DMP-266 dose increased to 600 mg/d after 36 weeks of treatment. By 44 weeks, 89% of the patients who received DMP266 plus Indinavir had PVL less than 400 copies/ml, and 77% of the patients who also were on D4T had PVL that were below the limits of detection. The regimens were generally well-tolerated, with only 2 persons in either treatment arm withdrawing because of side effects, which included infrequent rashes, but none that were severe or persistant. DMP-266 appears to be a very well tolerated new NNRTI compound which can be given once daily and adds to the potency of Indinavir therapy.
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.